Masimo (NASDAQ:MASI – Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.900-5.100 for the period, compared to the consensus estimate of 4.670. The company issued revenue guidance of -. Masimo also updated its FY 2024 guidance to 4.100-4.100 EPS.
Analyst Upgrades and Downgrades
MASI has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Wells Fargo & Company increased their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. BTIG Research boosted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Raymond James upped their target price on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Finally, Piper Sandler lifted their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.
Read Our Latest Report on MASI
Masimo Stock Performance
Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period last year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Masimo will post 4.03 earnings per share for the current year.
Masimo Company Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Recommended Stories
- Five stocks we like better than Masimo
- Using the MarketBeat Dividend Yield Calculator
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- What is the Australian Securities Exchange (ASX)
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.